Euronext-listed UCB, a Belgium-based global biopharmaceutical company focused on severe neurological and immunological conditions, has acquired the Patients Insights business of IMIDomics, a US-based biotechnology company focused on drug discovery…
Belgium: UCB strengthens in IMIDs with acquisition of IMIDomics’ Patient Insight business
…
…






